Dr Daniel Tillett, Chief Scientific Officer and Executive Director has advised that; “I chose to exercise my 4.25 million 9.9c options early for tax planning purposes. I have not sold any Race shares to fund the conversion, nor do I intend to sell any shares in the immediate or medium- term future. I believe Race Oncology has an extraordinary opportunity with Bisantrene and I look forward to seeing our clinical trial plans progress
Waking up to the greatest news.
Ann: Appendix 3Y - Dr Daniel Tillett, page-2
-
- There are more pages in this discussion • 113 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.94 |
Change
0.055(2.92%) |
Mkt cap ! $330.4M | |||
| Open | High | Low | Value | Volume |
| $1.89 | $1.96 | $1.85 | $333.0K | 174.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3105 | $1.94 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.95 | 7574 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |